HCPCS code J1568: Octagam immune globulin billing guide

Key Takeaways

HCPCS code J1568 reports one 500 mg unit of Octagam (immune globulin, intravenous, non-lyophilized) under Medicare Part B and most commercial payers.

CMS has designated Octagam as a single-dose container product, making JW or JZ modifier reporting mandatory on every J1568 claim since July 2023.

J1568 claims require supporting ICD-10-CM diagnosis codes that establish medical necessity; coverage follows LCD L35891 and CMS Article A57778.

Pabau’s claims management software links HCPCS codes, modifier logic, and clinical documentation in one workflow, reducing manual billing steps for infusion practices.

HCPCS code J1568 is the billing code for Octagam (immune globulin, intravenous, non-lyophilized), billed per 500 mg unit under Medicare Part B and most commercial payers. Accurate claims depend on correct unit counting, the required JW or JZ modifier, and a supporting ICD-10-CM diagnosis code.

Code description and clinical context for J1568

HCPCS code J1568 is the billing code for Octagam (immune globulin, intravenous, non-lyophilized), one of the most commonly billed IVIg products in outpatient and infusion settings. Every 500 mg of Octagam administered equals one billable unit of J1568.

Getting that unit count right before claim submission prevents underpayment and rework for billing teams at IV therapy practices and beyond. For another non-oral drug billing guide, review HCPCS code J1559: billing guide for Hizentra, a subcutaneous immune globulin product often discussed alongside IVIg.

The official 2026 descriptor reads: Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg. Octagam is manufactured by Octapharma and is supplied as a ready-to-use liquid, which is why the descriptor specifies “non-lyophilized.” Unlike powdered formulations that require reconstitution, Octagam does not need to be mixed before infusion, and that distinction matters for both clinical handling and billing documentation.

HCPCS code J1568 sits within HCPCS Level II, the code set maintained by the Centers for Medicare and Medicaid Services (CMS) to describe drugs, supplies, and services not covered by standard CPT codes. J-codes specifically cover drugs administered by routes other than oral method, spanning the range J0013 through J8999. J1568 is valid for the current 2026 HCPCS code set.

Key code properties

Medicare coverage and medical necessity for J1568

Medicare Part B covers IVIg when medical necessity is established through appropriate diagnosis coding. Coverage for J1568 follows MAC-specific LCDs (for example, Novitas LCD L35891) and is further governed by CMS Article A57778, Billing and Coding: Immune Globulin. Providers bear responsibility for selecting ICD-10-CM codes at the highest level of specificity for the year in which the service is rendered.

IVIg is typically covered under Medicare Part B for a defined list of FDA-approved indications, including primary immune deficiency disorders, immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). Off-label use requires strong documentation of medical necessity and is subject to MAC discretion.

Practices meeting IV hydration business requirements in their state still need to satisfy federal Medicare medical necessity standards separately. Transplant-related immunodeficiency diagnoses that may support IVIg use include ICD-10 code T86.10: unspecified issues of kidney transplant and ICD-10 code T86.31: heart-lung transplant rejection.

ICD-10-CM codes commonly paired with J1568

The ICD-10-CM diagnosis code on the claim must directly support the use of Octagam. Submit codes to the highest level of specificity available. Common pairings include:

• D83.9 – Common variable immunodeficiency, unspecified
• D80.1 – Nonfamilial hypogammaglobulinemia
• D69.3 – Immune thrombocytopenic purpura (ITP)
• G61.81 – Chronic inflammatory demyelinating polyneuritis (CIDP)
• G61.82 – Multifocal motor neuropathy (MMN)
• D84.9 – Immunodeficiency, unspecified
• D83.1 – Common variable immunodeficiency with predominant immunoregulatory T-cell disorders

CMS requires that the submitted medical record support every ICD-10-CM code billed. The FCSO Medicare provider bulletin for J1568 states explicitly that the CPT/HCPCS code must describe the service performed and the ICD-10-CM codes must be supported by the medical record. Insufficient diagnosis-level documentation is a leading cause of J1568 denials on Medicare audits.

JW and JZ modifier requirements for J1568

CMS has designated Octagam as a single-dose container drug. Since July 1, 2023, every J1568 claim submitted to Medicare must include either the JW or JZ modifier. Omitting the modifier causes claim rejection.

The CMS JW/JZ Modifier Policy lists J1568 by name. For related modifier and supply billing context, see the guide to HCPCS code A4211: supplies for self-administered injections. Build this modifier logic into your claim preparation workflow before submission to avoid correction loops later.

JW modifier: drug wastage billed

Use the JW modifier when medication is drawn from a single-dose vial but some portion is unused and discarded. The administered dose is billed on one line with the quantity of units given. The wasted amount is billed on a separate line with the JW modifier appended to J1568 and the quantity representing the discarded portion.

For example: a patient receives 2,500 mg of Octagam from a 3,000 mg single-dose vial. Bill 5 units of J1568 for the administered dose. Bill 1 unit of J1568-JW for the 500 mg wasted. Both lines require supporting documentation in the medical record, including the vial size, the dose administered, and a notation that the remainder was discarded.

JZ modifier: no drug wastage

Use the JZ modifier when the entire contents of the single-dose vial are administered with no waste. This certifies to the payer that no discardable drug existed. The JZ modifier appears on the single administered-dose claim line; there is no separate wastage line.

Selecting the correct modifier requires knowing the exact vial size used and the exact dose administered. Infusion nurses and clinical staff should document both figures in the treatment record at the time of service.

Practices that use an IV therapy intake form with a drug administration section can capture vial size and administered dose fields at the point of care, making modifier selection straightforward during the billing review.

Billing workflow and administration code pairing for J1568

J1568 reports the drug only. The infusion administration service is billed separately using CPT codes for intravenous infusion therapy. These two billing components appear on the same claim but on distinct lines.

• CPT 96365 – Intravenous infusion, for therapy/prophylaxis/diagnosis; initial, up to 1 hour
• CPT 96366 – Intravenous infusion; each additional hour (append once per additional hour beyond the first)

Both the drug and the administration code require place-of-service and referring provider information. For hospital outpatient departments, modifier APC rules may apply. Freestanding infusion centers and physician offices billing under the Physician Fee Schedule use the standard drug-plus-administration structure without APC bundling concerns.

Pabau’s claims management software allows infusion practices to associate HCPCS codes, modifiers, and administration CPT codes with treatment records and submit them as a linked claim, reducing the manual code-entry step between clinical documentation and the billing queue.

Practices running a mobile IV therapy business benefit from having that claim structure available without needing a separate billing platform. For other infused and injectable Part B drug billing guides, see HCPCS code J3380: Vedolizumab injection billing guide and HCPCS code J1306: Inclisiran 1 mg billing guide.

Automate your J-code billing workflows

Pabau links HCPCS codes, modifier logic, and clinical documentation in one place, so your team spends less time on manual claim preparation and more time on patient care.

Book a demo

Fee schedule and reimbursement for J1568

Medicare reimburses most Part B drugs under the Average Sales Price (ASP) + 6% methodology. CMS updates ASP-based reimbursement rates quarterly, so the rate in effect for a J1568 claim depends on the date of service, not the date of billing.

Always verify the current quarter’s rate using the CMS Physician Fee Schedule lookup tool before estimating patient out-of-pocket liability or confirming coverage with the patient.

Commercial payers may reimburse Octagam at contracted rates, AWP-based percentages, or via a specialty pharmacy carve-out. Practices using the buy-and-bill model purchase the drug directly and bill the payer after administration.

Those using a specialty pharmacy dispense arrangement bill only the administration code and receive drug reimbursement through the pharmacy channel separately. Understand which model applies for each payer before calculating expected margin on IVIg administration.

Prior authorization by payer type

Prior authorization requirements for J1568 vary by MAC, commercial plan, and diagnosis. Medicare Advantage plans often add prior authorization requirements beyond traditional Medicare. Commercial insurers may require step therapy (demonstrating failure of less expensive IVIg products) before approving Octagam specifically.

Practices should verify authorization requirements at the plan level before the first infusion, as unauthorized drug administration is typically not retroactively covered. Staff responsible for who can administer IV vitamin therapy decisions also need to coordinate auth status before scheduling. Step therapy may require documenting a failed trial of a lower-cost brand first, such as Gammaplex — see the HCPCS code J1557: billing guide for Gammaplex injection.

Related IVIg HCPCS codes and when to use each

Octagam is one of several IVIg brand products, each with its own HCPCS code. Billing the wrong code for the product administered is a compliance error. The Novitas IVIg Documentation Checklist groups these six codes together because auditors review them as a family. The brand name on the vial label determines the correct code.

All six codes share the same 500 mg per unit billing structure. A 10 g dose of any of these products bills as 20 units of the corresponding code. The distinction lies in the drug name.

Substituting one IVIg HCPCS code for another because the brand is unavailable that day is not an acceptable billing practice; the claim must reflect what was actually administered. Practices building formulary protocols should confirm current code descriptors before switching products by reviewing resources such as the HCPCS unclassified biologics billing guide.

Practices offering a range of infusion therapies benefit from having these code relationships mapped in their billing reference materials. When infusion nurses document the product name and billers know which code maps to that product, modifier selection and claim preparation require no manual lookup each visit.

Practices developing their referral pipeline can also find relevant context in the IV therapy marketing guide. For another commonly billed infusion-adjacent J-code, see the HCPCS code J1642: heparin sodium lock flush billing guide.

Documentation requirements for J1568 claims

CMS Article A57778 and MAC-level LCDs require the medical record to support both the diagnosis and the drug administration event. Missing documentation is the primary driver of J1568 claim denials and post-payment audit findings. Practices using digital forms for infusion intake and treatment records can capture required fields consistently, reducing the risk of incomplete documentation at audit.

A complete J1568 documentation set typically includes:

• Diagnosis supporting medical necessity (ICD-10-CM code with specificity)
• Physician order for Octagam including dose, frequency, and indication
• Drug administration record showing product name (Octagam), lot number, NDC, dose administered, and infusion start/stop times
• Vial size documentation for JW/JZ modifier determination
• Infusion nursing notes documenting patient monitoring, adverse reactions, and completion of infusion
• Prior authorization number (when required by payer)
• Referring or ordering provider NPI
• Place of service and provider type appropriate to the setting

The NDC (National Drug Code) must match the Octagam lot actually used. Some MACs require NDC reporting on the claim line in addition to the HCPCS code — check your MAC’s billing instructions, as requirements vary between Novitas, FCSO, and other contractors.

The best EMR for IV therapy comparison covers documentation requirements alongside system features for practices evaluating their workflow tools. For a related injectable drug billing reference, see the HCPCS code J9217: leuprolide acetate billing and units guide.

Billing J1568 accurately

Accurate J1568 billing requires four elements: correct unit count, the right JW or JZ modifier, supporting ICD-10-CM diagnosis codes, and a complete drug administration record. Any one of these missing will cause a claim rejection or create audit exposure.

Pabau’s IV therapy EMR software connects clinical documentation directly to claim preparation, so the product name, dose, vial size, and modifier decision flow into the billing queue from the treatment record rather than requiring a manual transfer.

For compounded or unclassified drug billing that sometimes arises alongside IVIg, see the guide to HCPCS code J7999: compounded drug, not otherwise classified. To see how Pabau handles J-code billing workflows for infusion practices, book a demo.

Continue your research

Running an IV therapy practice and need a compliance framework? IV therapy clinic best practices covers infusion safety protocols, regulatory requirements, and operational standards for outpatient infusion settings.

Reviewing the documentation requirements before your first IVIg infusion appointment? IV therapy intake form guidance walks through the clinical fields that support medical necessity documentation at the point of care.

Evaluating practice management tools for infusion billing? Best EMR for IV therapy compares platforms on documentation depth, HCPCS code support, and infusion-specific workflow features.

Frequently Asked Questions